ANTIBODIES TO ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS INADEQUATE RESPONDERS AND CLINICAL OUTCOMES AFTER AN ACTIVE SWITCH TO INFLIXIMAB

被引：0
|
作者：
Pool, C. [1 ]
Shankar, G. [2 ]
Schantz, A. [2 ]
Gunn, G. [2 ]
Bolce, R. [1 ]
Leirisalo-Repo, M. [3 ]
Wang, J. [2 ]
Goldman, J.
DeHoratius, R. [1 ]
Fleischmann, R. [4 ]
Decktor, D. [1 ]
机构：
[1] Janssen Serv LLC, Horsham, PA USA
[2] Janssen R&D LLC, Spring House, PA USA
[3] Helsinki U Cent Hosp, Helsinki, Finland
[4] Metroplex Clin Res Ctr, Dallas, TX USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [1] Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
    Pool, Chad
    Shankar, Gopi
    Schantz, Allen
    Gunn, George
    Bolce, Rebecca
    Leirisalo-Repo, Marjatta
    Wang, Jim
    Goldman, John A.
    DeHoratius, Raphael J.
    Fleischmann, Roy M.
    Decktor, Dennis
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S551 - S551
  • [2] Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study
    Fleischmann, Roy
    Goldman, John A.
    Leirisalo-Repo, Marjatta
    Zanetakis, Ellen
    El-Kadi, Hisham
    Kellner, Herbert
    Bolce, Rebecca
    DeHoratius, Raphael
    Wang, Jim
    Decktor, Dennis
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (11) : 2139 - 2149
  • [3] Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept
    Haraoui, B
    Keystone, EC
    Thorne, JC
    Pope, JE
    Chen, I
    Asare, CG
    Leff, JA
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (12) : 2356 - 2359
  • [4] PRESENCE OF ANTIBODIES TO ADALIMUMAB AND INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL REMISSION
    Eng, G.
    Fana, V.
    Omerovic, E.
    Hojsgaard, P.
    Lindegaard, H. M.
    Jensen, E. K.
    Bouchelouche, P. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 230 - 230
  • [5] Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients
    Brocq, O
    Albert, C
    Roux, C
    Gerard, D
    Breuil, V
    Ziegler, LE
    JOINT BONE SPINE, 2004, 71 (06) : 601 - 603
  • [6] Infliximab, Etanercept, and Adalimumab switching in patients with rheumatoid arthritis in the CORRONA database
    Dabbous, O.
    Kremer, J.
    Rambharose, J.
    El Taha, M.
    Reed, G.
    Tang, B.
    Thomson, H.
    Domdey, A.
    Rahman, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 42 - 42
  • [7] Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis
    Titos Arcos, Jose Carlos
    Hallal, Hacibe
    Robles, Mercedes
    Andrade, Raul J.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (05) : 282 - 284
  • [8] DOWN-TITRATION AND DISCONTINUATION OF INFLIXIMAB, ADALIMUMAB AND ETANERCEPT IN ESTABLISHED RHEUMATOID ARTHRITIS
    Lojo, L.
    Bonilla, G.
    Peiteado, D.
    Villalba, A.
    Plasencia, C.
    Nuno, L.
    Balsa, A.
    Martin-Mola, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 237 - 237
  • [9] THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS
    Lawson, R. W.
    Heatley, R. M.
    Johnson, K., I
    Khandker, R. K.
    Singh, A.
    VALUE IN HEALTH, 2010, 13 (07) : A308 - A308
  • [10] Dosing patterns and costs of adalimumab, etanercept, and infliximab among patients with rheumatoid arthritis
    Engel-Nitz, N. M.
    Huang, X.
    Globe, D.
    Baumgartner, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 260 - 260
12345